DermWire | Newest Articles http://practicaldermatology.com/dermwire/ Newest Articles en-us Thu, 27 Jul 2017 00:31:42 GMT Thu, 27 Jul 2017 00:31:42 GMT DermWire Study IDs Risk Factors for Melanoma in Kidney Transplant Recipients http://practicaldermatology.com/dermwire/view.asp?url=study-ids-risk-factors-for-melanoma-in-kidney-transplant-recipients Kidney transplant patients appear to be at a greater risk of developing melanoma than the general population and risk factors include being older, male and white, findings that corroborate results demonstrated in other studies, according to a new article published by JAMA Dermatology. Lifelong immunosuppressive therapy is among the complex lifestyle changes faced by renal transplant patients. The type, intensity and duration of immunosuppressive therapy contribute to the risk of developing sk… Wed, 26 Jul 2017 04:00:00 GMT Innovation in Action: Meet the DNA Sunscreen that Gets Better the Longer You Wear It http://practicaldermatology.com/dermwire/view.asp?url=innovation-in-action-meet-a-dna-sunscreen-that-gets-better-the-longer-you-wear-it Researchers at Binghamton University, State University of New York have developed a coating made out of DNA that gets better at protecting skin from Ultraviolet light the more you expose it to the sun, and it also keeps your skin hydrated. “Ultraviolet (UV) light can actually damage DNA, and that’s not good for the skin,” explains study author Guy German, assistant professor of biomedical engineering at Binghamton University. “We thought, let’s flip it. What happ… Wed, 26 Jul 2017 04:00:00 GMT Simulation Techniques Help Medical Students Empathize with Melanoma Patients http://practicaldermatology.com/dermwire/view.asp?url=simulation-techniques-help-medical-students-empathize-with-melanoma-patients Simulation techniques can allow doctors to experience what it feels like to be a melanoma patient. The study, which is led by Queen’s University in Belfast collaboration with researchers from the University of Huddersfield and University College Dublin, appears in the British Journal of Dermatology. As part of the study, medical students were encouraged to wear a highly realistic temporary tattoo of a malignant melanoma before listening to an audio account of a patient sharing their … Wed, 26 Jul 2017 04:00:00 GMT Histogen’s Growth Factor Technology Now Part of Allergan's Skin Care Line http://practicaldermatology.com/dermwire/view.asp?url=histogens-growth-factor-technology-now-part-of-allergan-skin-care-line Histogen’s growth factor technology will be marketed as part of Allergan's skin care line within its recently acquired Regenica® Advanced Rejuvenation System. The Regenica line is based on multipotent CCM Complex (Cell Conditioned Media) which comprises active growth factors and proteins. “Histogen has developed a next-generation regenerative cell technology, harnessing the power of growth factors and stem-cell signaling molecules for skin rejuvenation that complements … Tue, 25 Jul 2017 04:00:00 GMT Early Use of CO2 Lasers on Surgical Scars Bests Silicone Gel Treatment http://practicaldermatology.com/dermwire/view.asp?url=early-use-of-co2-lasers-on-surgical-scars-bests-silicone-gel-treatment Early treatment of surgical scars with a super-pulsed fractional C02 laser shows promise, new research suggests. The study, which appears in Lasers in Surgery and Medicine (LSM), found that laser treatment of elective surgery scars within the first weeks resulted in improved texture and pigment compared with standard silicone gel treatment. The research was selected as Editor’s Choice in the August 2017 issue of LSM. “Applications using fractional CO2 lasers, widely used to … Mon, 24 Jul 2017 04:00:00 GMT FDA Expands Approval of Yervoy to Include Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma http://practicaldermatology.com/dermwire/view.asp?url=fda-expands-approval-of-yervoy-to-include-pediatric-patients-12-years-and-older-with-unresectable-or-metastatic-melanoma The FDA has expanded the indication for Bristol-Myers Squibb's Yervoy (ipilimumab) injection for intravenous use to now include the treatment of unresectable or metastatic melanoma in pediatric patients 12 years of age and older. Yervoy was evaluated in two trials of pediatric patients: a dose-finding study in 33 patients aged two to 21 years with relapsed or refractory solid tumors and an open-label, single-arm trial in 12 adolescents (ages ranging from 12 to 16 years) with previously treat… Mon, 24 Jul 2017 04:00:00 GMT LEO Pharma Receives EU Marketing Authorization for Kyntheum to Treat Plaque Psoriasis http://practicaldermatology.com/dermwire/view.asp?url=leo-pharma-receives-eu-marketing-authorization-for-kyntheumfor-the-treatment-of--plaque-psoriasis The European Commission has granted marketing authorisation for LEO Pharma's Kyntheum (brodalumab), a new biologic for the treatment of moderate-to-severe plaque psoriasis in adults within the European Union who are candidates for systemic therapy. Kyntheum selectively targets the IL-17 receptor subunit A. By specifically binding to the receptor on skin cells rather than targeting free floating inflammatory mediators, brodalumab blocks the biological activity of several pro-inflammatory IL-1… Thu, 20 Jul 2017 04:00:00 GMT DermTech Secures Billing Codes for its Proprietary Melanoma Test http://practicaldermatology.com/dermwire/view.asp?url=dermtech-secures-billing-codes-for-its-proprietary-melanoma-test The American Medical Association (AMA) has granted DermTech, Inc. Category 1, Tier 2 Molecular Pathology procedure codes related to its proprietary test for the detection of melanoma related gene expression. The company has secured this Common Procedural Terminology (CPT) coding for LINC and PRAME, the two primary genes included in the pigmented lesion assay, the company's non-invasive biopsy and gene expression test for skin cancer. These genes will be added to the approved list for CPT cod… Wed, 19 Jul 2017 04:00:00 GMT Joseph H. Boccuzi Appointed to Allergan plc Board of Directors http://practicaldermatology.com/dermwire/view.asp?url=joseph-h-boccuzi-appointed-to-allergan-plc-board-of-directors Allergan plc has named Joseph H. Boccuzi to its Board of Directors, effective immediately. Mr. Boccuzi recently retired as a Partner in the Global Life Sciences, Board and Chief Executive Officer Practices at Spencer Stuart, following 24 years of service with the global executive search and leadership consulting firm. "Talented people give Allergan an edge as we continue to build our Bold culture and drive long-term sustainable growth," said Brent Saunders, Chairman and Chief Execu… Wed, 19 Jul 2017 04:00:00 GMT Valeant to Sell Obagi Medical Products Business for $190 M http://practicaldermatology.com/dermwire/view.asp?url=valeant-to-sell-obagi-medical-products-business-for-190-m Valeant Pharmaceuticals International, Inc. has entered into an agreement to sell its Obagi Medical Products business for $190 million in cash to Haitong International Zhonghua Finance Acquisition Fund I, L.P. Limited partners of the Fund include industry veterans in other geographic markets, such as China Regenerative Medicine International Limited. "The sale of Obagi marks additional progress in our efforts to streamline our operations and reduce debt," Joseph C. Papa, chairman an… Tue, 18 Jul 2017 04:00:00 GMT Paratek: Phase 3 Study of Oral-Only Dosing of Omadacycline Met FDA and EMA Efficacy Endpoints in Acute Bacterial Skin Infections http://practicaldermatology.com/dermwire/view.asp?url=paratek-phase-3-study-of-oral-only-dosing-of-omadacycline-met--fda-and-ema-efficacy-endpoints-in-acute-bacterial-skin-infections Paratek Pharmaceuticals, Inc. shared positive top-line results from a pivotal Phase 3 study comparing its once-daily, oral investigational antibiotic, omadacycline, to twice-daily oral linezolid in the treatment of acute bacterial skin and skin structure infections (ABSSSI). The study met all of its primary and secondary endpoints required to support approval for this indication by the FDA and the European Medicines Agency (EMA). This represents the third positive Phase 3 registration study of o… Mon, 17 Jul 2017 04:00:00 GMT Galderma CareConnect Patient Savings Card Program Passes Milestone http://practicaldermatology.com/dermwire/view.asp?url=galderma-careconnect-patient-savings-card-program-passes-milestone The Galderma CareConnect patient savings program has surpassed the mark of 1,000,000 prescriptions filled through its patient access program. Committed to keeping accessibility remarkably simple and saving patients’ money, the company says the program is structured to work at any accredited retail, mail-order or independent pharmacy across the country that accepts patient rebate cards by offering discounts on the quality dermatology products offered by Galderma Laboratories, L.P. To dat… Mon, 17 Jul 2017 04:00:00 GMT Patent Challenge Filed for Generic Version Of Soolantra Cream http://practicaldermatology.com/dermwire/view.asp?url=patent-challenge-filed-for-generic-version-of-soolantra-cream Perrigo Company plc's subsidiary has filed a Paragraph IV Abbreviated New Drug Application with the FDA for a generic version of Soolantra® (ivermectin) cream, 1%. Following notification from Perrigo, Galderma Laboratories, L.P., Galderma S.A., and Nestle Skin Health S.A., filed a patent litigation suit asserting patents listed in the Orange Book for Soolantra in the United States District Court for the Northern District of Texas on July 13, 2017. This action formally initiates the li… Mon, 17 Jul 2017 04:00:00 GMT Syneron Candela Completes Transaction with Funds Advised by Apax Partners; Becomes a Private Company http://practicaldermatology.com/dermwire/view.asp?url=syneron-candela-completes-transaction-with-funds-advised-by-apax-partners-becomes-a-private-company Syneron Medical Ltd. announced the successful completion of its acquisition by an affiliate of funds advised by Apax Partners for $11.00 per share in cash in a transaction valued at approximately $400 million. The transaction was announced on April 3, 2017 and received approval from Syneron Candela's shareholders on June 15, 2017. As a result of the transaction, Syneron Candela is now a privately held company. Syneron Candela's ordinary shares ceased to trade on The Nasdaq Stock Mark… Mon, 17 Jul 2017 04:00:00 GMT Tomatoes May Slash Skin Cancer Risk http://practicaldermatology.com/dermwire/view.asp?url=tomatoes-may-slash-skin-cancer-risk Daily tomato consumption may cut skin cancer risk in half, according to a new study in mice. The Ohio State University researchers report their findings online in the journal Scientific Reports. Male mice fed a diet of 10 percent tomato powder daily for 35 weeks, who were then exposed to ultraviolet light, experienced, on average, showed a 50 percent decrease in skin cancer tumors compared to mice that did not eat the tomato powder. The skin cancer protection is likely coming from the c… Fri, 14 Jul 2017 04:00:00 GMT FDA Approves Janssen's Tremfya for Moderate To Severe Plaque Psoriasis http://practicaldermatology.com/dermwire/view.asp?url=fda-approves-janssens-tremfya-for-moderate-to-severe-plaque-psoriasis The FDA has approved Janssen's Tremfya (guselkumab) for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Tremfya is the first and only approved biologic therapy that selectively blocks only IL-23, a cytokine that plays a key role in plaque psoriasis. Approval comes after an expedited regulatory review following application of an FDA Priority Review Voucher. Tremfya is administered as a 100mg subcutaneous injection every… Thu, 13 Jul 2017 04:00:00 GMT FDA Clears Philips BlueControl Wearable Light Therapy Device to Treat Mild Psoriasis At Home http://practicaldermatology.com/dermwire/view.asp?url=fda-clears--philips-bluecontrol-wearable-light-therapy-device-to-treat-mild-psoriasis-at-home The FDA has granted Royal Philips 510(k) clearance to market the Philips BlueControl wearable light therapy device to treat mild psoriasis. In the US, BlueControl is a Class II prescription medical device designed for home use. Clinical studies have demonstrated that the UV-free blue LED light emitted by Philips' BlueControl wearable device induces natural, drug-free processes in the skin to significantly reduce symptoms of mild psoriasis vulgaris, such as redness, scaling, and thickness … Thu, 13 Jul 2017 04:00:00 GMT Allergan CEO: Consensus Needed on Medical Aesthetic Treatment in Minors http://practicaldermatology.com/dermwire/view.asp?url=allergan-ceo-consensus-needed-on-medical-aesthetic-treatment-in-minors Allergan Chairman & CEO Brent Saunders, the father of two high school-aged girls, is speaking up and out about the risks associated with offering medical aesthetic treatments to minors. In a new blog post, he writes “we must remember that anyone under the age of 18 is still maturing. Their body and appearance is still changing.” Saunders is calling for dialogue between all stakeholders in this industry -- medical aesthetic product manufacturers, plastic surgeons, dermatol… Wed, 12 Jul 2017 04:00:00 GMT Derms Urged to Step Up Role in Antibiotic Stewardship http://practicaldermatology.com/dermwire/view.asp?url=derms-urged-to-step-up-role-in-antibiotic-stewardship Dermatologists can and should play a larger role in antibiotic stewardship, according to researchers out of Perelman School of Medicine at the University of Pennsylvania in Philadelphia. Data from the CDC shows the average dermatology provider wrote 669 antibiotic prescriptions in 2014, the most recent year for which data are available. That is, by far, the highest average of any provider specialty. For some perspective, the next closest group was primary care physicians, who wrote an average… Wed, 12 Jul 2017 04:00:00 GMT Dr. Jacqualyn Fouse Named Executive Chairman of Dermavant http://practicaldermatology.com/dermwire/view.asp?url=dr-jacqualyn-fouse-named-executive-chairman-of-dermavent Dr. Jacqualyn "Jackie" Fouse is the new Executive Chairman of Dermavant Sciences. Part of the Roivant Sciences family of companies, Dermavant Sciences is developing and, upon regulatory approval, commercializing three investigational drugs RVT-501, RVT-502, and RVT-201. RVT-501 is a highly potent and selective topical phosphodiesterase-4 inhibitor currently in a Phase 2 clinical program for patients with mild-to-moderate atopic dermatitis. RVT-502, also known as cerdulatinib, is a d… Mon, 10 Jul 2017 04:00:00 GMT High Doses of Sunshine Vitamin May Improve Sunburn http://practicaldermatology.com/dermwire/view.asp?url=high-doses-of-sunshine-vitamin-may-improve-sunburn High doses of vitamin D taken one hour after sunburn may significantly reduce skin redness, swelling, and inflammation, according to double-blinded, placebo-controlled clinical trial out of Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center. The trial results appear in the Journal of Investigative Dermatology. In the study, 20 participants were randomized to receive a placebo pill or 50,000, 100,000, or 200,000 IU of vitamin D one hour afte… Fri, 7 Jul 2017 04:00:00 GMT FOREO’s New At-Home Blue Light Acne Pen Hits the US and Canada http://practicaldermatology.com/dermwire/view.asp?url=foreos-new-at-home-blue-light-acne-pen-hits-the-us-and-canada FOREO's blue-light acne pen is now available in 333 stores in the US and Canada with more to be added by September 2017. The FOREO ESPADA comprises 415 nanometers (nm) of blue light energy combined with red cross-hair targeting that converges as ESPADA approaches the skin so users can zero-in on acne-affected areas. In addition, FOREO’s unique T-Sonic pulsations stimulate the skin, increasing in strength over the course of the treatment and forcing light into the deepest layers. T-S… Thu, 6 Jul 2017 04:00:00 GMT Samsung Biologics to Manufacture Sun Pharma’s Tildrakizumab for Psoriasis http://practicaldermatology.com/dermwire/view.asp?url=samsung-biologics-to-manufacture-sun-pharmas-tildrakizumab-for-psoriasis Sun Pharmaceutical Industries just inked a long-term agreement with South Korea’s Samsung BioLogics to manufacture Tildrakizumab for psoriasis. The investigational IL-23p19 inhibitor drug is currently under review by the US Food & Drug Administration (FDA) and the European Medicines Agency (EMA) for moderate to severe psoriasis Sun Pharma acquired the rights of the molecule from MSD, known as Merck in the US and Canada, for $80 million in 2014 to grow its position in dermatology.… Wed, 5 Jul 2017 04:00:00 GMT Array BioPharma Submits NDAs for Binimetinib and Encorafenib in Advanced Melanoma http://practicaldermatology.com/dermwire/view.asp?url=array-biopharma-submits-ndas-for-binimetinib-and-encorafenib-in-advanced-melanoma Array BioPharma submitted two New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA) for the use of the combination of binimetinib 45 mg twice daily and encorafenib 450 mg once daily (COMBO450) for the treatment of patients with BRAF-mutant advanced, unresectable or metastatic melanoma. Binimetinib is a late-stage small molecule MEK inhibitor and encorafenib is a late-stage small molecule BRAF inhibitor, both of which target key enzymes in the MAPK signaling pathway (RAS-… Wed, 5 Jul 2017 04:00:00 GMT Study: Soolantra is Both Anti-Inflammatory and Anti-Demodex http://practicaldermatology.com/dermwire/view.asp?url=study-soolantra-is-both-anti-inflammatory-and-anti-demodex A recently published study sought to find scientific rationale for the dual anti-inflammatory and anti-parasitic mode of action of topical ivermectin 1% cream (Soolantra) in patients with rosacea. In a monocentric pilot study, 20 Caucasian patients with moderate to severe rosacea, as assessed by investigator global assessment (IGA score ≥ 3) and a demodex density ≥ 15/cm2, were treated with topical ivermectin 1% cream once daily for ≥12 weeks. The density of Demodex mites was assesse… Wed, 5 Jul 2017 04:00:00 GMT